<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897126</url>
  </required_header>
  <id_info>
    <org_study_id>LESS202010</org_study_id>
    <nct_id>NCT04897126</nct_id>
  </id_info>
  <brief_title>Effect of MUSK Pill on the Patients With Chest Pain Due to Non Obstructive Coronary Artery Disease</brief_title>
  <acronym>LESS</acronym>
  <official_title>Efficacy and Safety of MUSK Pill on the Patients With Chest Pain Due to Non Obstructive Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Hutchison Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinshan Hospital Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Hutchison Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients&#xD;
      were treated with the trial drug or placebo in a 1:1 ratio. The control group was treated&#xD;
      with placebo 4 pills / day, 3 times / day on the basis of conventional treatment until the&#xD;
      end of follow-up, while the experimental group was treated with MUSK Pill 4 pills / day, 3&#xD;
      times / day on the basis of conventional treatment until the end of follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 stratified block random grouping according to the center</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Seattle angina pectoris scale</measure>
    <time_frame>12 weeks ± 1 week</time_frame>
    <description>Main evaluation indicators</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average number of angina attacks per week</measure>
    <time_frame>12 weeks ± 1 week</time_frame>
    <description>Secondary evaluation index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total dosage of sublingual nitroglycerin buccal tablets</measure>
    <time_frame>12 weeks ± 1 week</time_frame>
    <description>Secondary evaluation index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Seattle Angina scale item score</measure>
    <time_frame>12 weeks ± 1 week</time_frame>
    <description>Secondary evaluation index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of angina pectoris classification in CCS</measure>
    <time_frame>12 weeks ± 1 week</time_frame>
    <description>Secondary evaluation index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of major cardiovascular events (MACE)</measure>
    <time_frame>12 weeks ± 1 week</time_frame>
    <description>Secondary evaluation index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the incremental cost-effectiveness ratio (ICER) was used as the evaluation index</measure>
    <time_frame>12 weeks ± 1 week</time_frame>
    <description>Pharmacoeconomic evaluation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Non Obstructive Coronary Artery Disease</condition>
  <condition>Angina Pectoris</condition>
  <condition>Coronary Heart Disease</condition>
  <condition>X Syndrome, Angina</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group was given placebo 4 capsules / day, 3 times / day, until the end of follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MUSK Pill</intervention_name>
    <description>On the basis of routine treatment, MUSK Pills were added to 4 capsules / day, 3 times per day until the end of follow-up.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The age was 18-75 years old, and the gender was not limited;&#xD;
&#xD;
          -  The clinical diagnosis of angina pectoris or angina pectoris equivalent symptoms&#xD;
             (attack at least twice a week), and coronary CTA or coronary angiography examination&#xD;
             of coronary artery normal or lesions &lt; 50%;&#xD;
&#xD;
          -  Willing to follow up and sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients were selected and had no angina pectoris without medication&#xD;
&#xD;
          -  The maximum lesions of major branches of major vessels were ≥ 50% in CTA or&#xD;
             angiographic examination;&#xD;
&#xD;
          -  Severe cardiovascular and pulmonary vascular diseases: stubborn heart failure or&#xD;
             cardiogenic shock, hypertrophic obstructive cardiomyopathy, severe aortic stenosis,&#xD;
             incomplete closure, aortic dissection, pulmonary embolism;&#xD;
&#xD;
          -  There were three months of acute myocardial infarction;&#xD;
&#xD;
          -  Severe respiratory disease, COPD or active pulmonary infection;&#xD;
&#xD;
          -  Although the patients with poor blood pressure control were treated with hypertension,&#xD;
             the hypertension was not controlled and / or systolic pressure ≥ 180mmhg and diastolic&#xD;
             pressure ≥ 110mmhg before the end of screening period;&#xD;
&#xD;
          -  Severe liver and kidney diseases, such as liver and kidney dysfunction (alt, AST ≥ 1.5&#xD;
             times of the upper limit of normal value, Cr &gt; 1.5 times of normal value), active&#xD;
             liver disease, cirrhosis or uremia patients;&#xD;
&#xD;
          -  Any other serious diseases or conditions such as malignant tumor, severe anemia,&#xD;
             severe renal artery stenosis, severe anxiety depression (HAMD-17) and suicide or&#xD;
             maniac mental illness;&#xD;
&#xD;
          -  Participated in other clinical studies within 30 days before the selection, or is&#xD;
             currently participating in other clinical studies;&#xD;
&#xD;
          -  Pregnant, lactating women and women and men with recent birth plans;&#xD;
&#xD;
          -  Allergic constitution or allergy to known components of the study drug;&#xD;
&#xD;
          -  The researchers judged that the patients who were not suitable for the study were not&#xD;
             suitable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chun Liang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Changzheng Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chun Liang</last_name>
    <phone>+8613801731588</phone>
    <email>chunliangliang@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui Chen</last_name>
    <phone>+8615026930037</phone>
    <email>Chenhui_64@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun Liang</last_name>
      <phone>+8613801731588</phone>
      <email>chunliangliang@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Shexiang Baoxin Pill</keyword>
  <keyword>Musk pill</keyword>
  <keyword>patients with chest pain due to non obstructive coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Microvascular Angina</mesh_term>
    <mesh_term>Chest Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

